SK Biopharmaceuticals Forecast, price target & analysts
SK Biopharmaceuticals Target price 2026 - Analyst rating & recommendation
SK Biopharmaceuticals Classifications & Recommendation
SK Biopharmaceuticals Price Target
| Target Price | ₩153,000.00 |
| Price | ₩76,900.00 |
| Potential | |
| Number of Estimates | 19 |
| 19 Analysts have issued a price target SK Biopharmaceuticals 2027 . The average SK Biopharmaceuticals target price is ₩153,000.00. This is higher than the current stock price. The highest price target is , the lowest is . | |
| A rating was issued by 21 analysts: 18 Analysts recommend SK Biopharmaceuticals to buy, 2 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the SK Biopharmaceuticals stock has an average upside potential 2027 of . Most analysts recommend the SK Biopharmaceuticals stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion ₩ | ??? | ??? |
| ??? | ??? | |
| EBITDA Margin | ??? | ??? |
| ??? | ??? | |
| Net Margin | ??? | ??? |
| ??? | ??? |
19 Analysts have issued a sales forecast SK Biopharmaceuticals 2026 . The average SK Biopharmaceuticals sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
17 Analysts have issued an SK Biopharmaceuticals EBITDA forecast 2026. The average SK Biopharmaceuticals EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
18 SK Biopharmaceuticals Analysts have issued a net profit forecast 2026. The average SK Biopharmaceuticals net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share ₩ | ??? | ??? |
| ??? | ??? | |
| P/E | ??? | |
| EV/Sales | ??? |
18 Analysts have issued a SK Biopharmaceuticals forecast for earnings per share. The average SK Biopharmaceuticals EPS is
. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .This results in the following potential growth metrics and future valuations:
SK Biopharmaceuticals...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
